The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA
Open accessAbstract
This study reports on the design of mRNA and adjuvant-loaded lipid nanoparticles for therapeutic cancer vaccination. The use of nucleoside-modified mRNA has previously been shown to improve the translational capacity and safety of mRNA-therapeutics, as it prevents the induction of type I interferons (IFNs). However, type I IFNs were identified as the key molecules that trigger the activation of antigen presenting cells, and as such drive T cell immunity. We demonstrate that nucleoside-modified mRNA can be co-delivered with the clinically approved TLR agonist monophosphoryl lipid A (MPLA). As such, we simultaneously allow high antigen expression in vivo while substituting the type I IFN response by a more controllable adjuvant. This strategy shows promise to induce effective antigen-specific T cell immunity and may be useful to enhance the safety of mRNA vaccines.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several preclinical studies have indicated that an unmodified mRNA platform induces a more pronounced type-I IFN-polarized innate immune response [11,62]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [62]
In the citing paper
“In comparison, cationic mRNA LNPs composed of a cationic lipid and cholesterol, or DOPE were found to primarily target the lungs, where they transfect tissueresident DCs, macrophages and endothelial cells [142,157,158].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [157]
In the citing paper
“Comparative studies performed by our research group and others demonstrated that nucleoside-modified mRNA LNPs outperformed unmodified mRNA LNPs in translation capacity, but failed to elicit successful CTL responses due to the drastically reduced production of type I IFNs [119,157].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [157]
In the citing paper
“In a proof-of-concept study, we demonstrated that nucleoside-modified mRNA can be co-delivered with the clinically approved TLR agonist MPLA, achieving functional CTL responses like unmodified mRNA, but with strongly reduced type I IFN responses [157].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [157]
Citations
Cites
Proceedings of the National Academy of Sciences of the United States of America
Dowling, J. E., & Wald, G. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1981.tb06752.x · Cited by 17,937
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Biomolecular coronas provide the biological identity of nanosized materials
Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.207 · Cited by 3,017
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–131 of 131
RNA Ligation for Mono and Dually Labeled RNAs
Depaix, A., Młynarska-Cieślak, A., Warmiński, M., Sikorski, P. J., Jemielity, J., & Kowalska, J. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202101909 · Cited by 10
D’haese, S., Laeremans, T., den Roover, S., Allard, S. D., Vanham, G. L., & Aerts, J. L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071387 · Cited by 10
Manicum, A.-L. E., Sargazi, S., Razzaq, S., Kumar, G. V., Rahdar, A., Zeybekler, S. E., Ain, Q. U., Bilal, M., & Aboudzadeh, M. A. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103288 · Cited by 9
Nanoimmunotherapy – cloaked defenders to breach the cancer fortress
Kandasamy, G., Annenkov, V. V., & Krishnan, U. M. (2018) · Nanotechnology Reviews · doi:10.1515/ntrev-2018-0013 · Cited by 9
A bi-adjuvant nanovaccine amplifying STING activation for cancer immunotherapy
Liu, D., Liang, S., Ma, K., Yun, K., Zhou, M., Yao, J., Hai, L., Peng, Y., & Wang, Z. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102372 · Cited by 8
mRNA Vaccination: An Outlook on Innate Sensing and Adaptive Immune Responses
Doost, J. S., Fazel, F., Boodhoo, N., & Sharif, S. (2024) · Viruses · doi:10.3390/v16091404 · Cited by 9
Innate sensing and cellular metabolism: role in fine tuning antiviral immune responses
Ahmed, D., Daraawi, M. A., & Cassol, E. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiac011 · Cited by 8
Engineering Delivery Technologies for Optimizing mRNA Vaccines
Gu, T., Yan, X., & Liu, S. (2025) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00032 · Cited by 7
Choi, H., Lee, S., Kim, H., Bae, S., Jo, S., Kim, J., Lee, Y., Ha, D., Oh, A., Yoon, S., et al. (2025) · Journal of Biological Engineering · doi:10.1186/s13036-025-00573-1 · Cited by 6
Controlling Protein Expression by Delivery of RNA Therapeutics Using Lipid Nanoparticles
Lin, P. J. C., & Tam, Y. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814470-1.00009-5 · Cited by 6
Messenger RNA and Plasmid DNA Vaccines for the Treatment of Cancer
Moseman, J. E., Shim, D., Jeon, D., Rastogi, I., Schneider, K. M., & McNeel, D. G. (2025) · Vaccines · doi:10.3390/vaccines13090976 · Cited by 5
Zhang, Y., Béland, L., Roussel, S., Bertrand, N., Hébert, S. S., & Vallières, L. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae059 · Cited by 6
Therapeutic Potential of HNF4α in End-stage Liver Disease
Díaz‐Aragon, R., Coard, M. C., Amirneni, S., Faccioli, L. A. P., Haep, N., Malizio, M. R., Motomura, T., Kocas‐Kilicarslan, Z. N., Ostrowska, A., Florentino, R. M., et al. (2021) · Organogenesis · doi:10.1080/15476278.2021.1994273 · Cited by 5
Recent Advances in mRNA Therapeutic Cancer Vaccines
Laflin, A. D., Pan, J., You, M., & Jiang, S. (2026) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110824-034150 · Cited by 4
Roy, A. A., Jain, N., Pokale, R., Madhusoodanan, G., Mukharya, A., Farhana, S. A., Rao, B. S. S., Goda, J. S., & Mutalik, S. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126862 · Cited by 4
Critical applications and prospects of RNA modification in mRNA vaccines
Liu, C., Peng, J., Zhang, M., Xiang, H., & Yi, C. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0800 · Cited by 2
Improving the Efficacy of Cancer mRNA Vaccines
Kirtane, A. R., & Traverso, G. (2025) · The Cancer Journal · doi:10.1097/ppo.0000000000000764 · Cited by 3
Formulation screening for local delivery of mRNA and photosensitizer to treat superficial tumor
Huang, L., Tang, S., Guo, J., Tu, Y., Li, S., Yang, T., Zhao, D. B., & Wang, C. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107525 · Cited by 2
Wang, R., Zhang, Z., Wang, Q., Gu, P., Yang, Y., Wang, B., & Teng, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s580526 · Cited by 5
Advancing Cancer Vaccines with Radionuclide Imaging
Cheng, S., Long, X., Zhang, Y., Lan, X., & Jiang, D. (2024) · Small · doi:10.1002/smll.202406950 · Cited by 2
Phua, K. K. L., Liu, Y., Zhang, W., Chin, J. M., Tang, H.-W., Pardi, N., & Nair, S. K. (2026) · Scientific Reports · doi:10.1038/s41598-026-35611-5 · Cited by 1
Nucci, G., Vitale, C., Girolamo, A. D., Silvestri, N., Persano, S., Gjurgjaj, L., Bottino, C., Castriconi, R., & Pellegrino, T. (2026) · Small Methods · doi:10.1002/smtd.202502416 · Cited by 2
Adjuvants, the Elephant in the Room for RNA Vaccines
D’haese, S., den Roover, S., & Aerts, J. L. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_12 · Cited by 1
Transcriptional Targeting of Dendritic Cells Using an Optimized Human Fascin1 Gene Promoter
Zeyn, Y., Hobernik, D., Wilk, U., Pöhmerer, J., Hieber, C., Medina‐Montano, C., Röhrig, N., Strähle, C. F., Thoma‐Kress, A. K., Wagner, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316938 · Cited by 1
Yi, Q., Liu, J., Kurban, A., Li, J., Luo, H., & Sun, J. (2020) · PubMed Central · doi:10.12122/j.issn.1673-4254.2020.05.25 · Cited by 1
He, X. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738957376.793579986
Cancer Vaccines Based on mRNA: Hype or Hope?
de Mey, W., Autaers, D., Bertazzon, G., Esprit, A., Aragon, M. M., Franceschini, L., & Breckpot, K. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch13
Self-citationSon, J., Yoo, H., Park, J., Park, H., Chong, S., Lee, J., Kim, J., Park, E., Bae, S.-H., Kang, S.-H., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102697
Immunoengineering-gene delivery
Arabi, L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21521-6.00003-x
Moseman, J. E., Brinkman, H. M., Choe, J. A., Shim, D., Burger, J. C., Ferraresso, F., Rastogi, I., Kastrup, C. J., Murphy, W. L., & McNeel, D. G. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201698
Linares-Fernández, S. (2021) · theses.fr (ABES) · doi:10.70675/17ec09cezeb11z45f7z8529z7ffbf89d664a
Metadata
- Authors
- Verbeke, R., Lentacker, I., Wayteck, L., Breckpot, K., Van Bockstal, M., Descamps, B., Vanhove, C., De Smedt, S. C., & Dewitte, H.
- Affiliations
- Ghent University Hospital (BE)
- Vrije Universiteit Brussel (BE)
- Ghent University (BE)
- ORCID
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 266
- Pages
- 287-300
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2762387202
- Cited by
- 132
- References
- 66
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 15 · 2023: 14 · 2022: 20 · 2021: 20 · 2020: 16 · 2019: 17 · 2018: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- FWO (G016513N, G0B2814N)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- nucleoside-modified mRNA, TLR agonists, monophosphoryl lipid A, lipid nanoparticles, cancer immunotherapy, mRNA vaccines, type I interferon, adjuvants, antigen-presenting cells, T cell immunity
- MeSH terms
- Animals, Cytidine, Dendritic Cells, Female, Immunotherapy, Lipid A, Lipids, Mice, Inbred C57BL, Neoplasms, RNA, Messenger, Cancer Vaccines, Toll-Like Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
